本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
The 100% Pure Cotton Compressed Balls Combine Highly Concentrated Glycolic Acid and Salicylic Acid For Intensive Spot Care, Pore Purification, and Excessive Sebum Care SEOUL, South Korea, June 16, 2023 /PRNewswire/ -- COSRX has announced the release of their new The AHA 2 BHA 2 Blemish Treatment Serum that boasts 2% AHA & 2% BHA within 100% pure cotton compressed balls to provide a quick and effective solution for spot care and blemish needs. Designed to be hygienic, quick, and easy to use, this serum is a game-changer for anyone seeking effective spot care without the hassle. COSRX LAUNCHES THE AHA 2 BHA 2 BLEMISH TREATMENT SERUM The innovative new serum brings together an optimal blend of ingredients such as PHA (Gluconolacton), Allantoin, Zinc PCA, and Sodium Hyaluronate which together become the ideal derm solution for anyone aiming to prevent their spots from getting bigger or worse. Beyond just treating spots, the serum also addresses whiteheads, blackheads, excess sebum, and clogged pores for a solution that is suitable for those of all skin types. With just one cotton ball, you can now treat your spots without the need to touch them directly. This hygienic approach ensures a clean and convenient application. Simply tap-tap the spot you want to target, and let the serum work its magic. The cotton ball is the perfect size and shape for precise application on the targeted area, making spot treatment a breeze. "Our The AHA 2 BHA 2 Blemish Treatment Serum with the DermCottonBall offers a hygienic, quick, and easy solution," stated a COSRX spokesperson. "We recognize the importance of providing an effective spot treatment that prioritizes cleanliness and ease of use. With our serum, you can confidently address your spots without any hassle." Attention to both the skin and earth is key - the 100% pure cotton balls have a variety of certification marks which include Vegan® Fabric, Biodegradable Fabric, LOHAS (Life Style of Health and Sustainability) and OEKO-TEX® (Oeko-Tex Standard 100). The AHA 2 BHA 2 Blemish Treatment Serum is available on the following official sites: Shopee Singapore; Shopee Philippines; Shopee Vietnam; Shopee Thailand; Shopee Taiwan ; Shopee Malaysia. About COSRX With its powerful yet affordable skincare solutions, COSRX has quickly become one of America's favorite skincare brands. Using a minimal number of highly effective natural extracts in concentrated doses, COSRX products deliver visible results by treating skin with only the essentials it needs and nothing it doesn't. Find its best-selling skincare solutions at retailers nationwide, including Amazon, ULTA, JCPenney, Target and Dermstore. Instagram: https://www.instagram.com/cosrx/ TikTok: https://www.tiktok.com/@cosrx_official COSRX Official Website: https://www.cosrx.com/
BRISTOL, England, June 16, 2023 /PRNewswire/ -- Citi Treasury and Trade Solutions (TTS) and Pismo, the next-gen banking and payments software company, jointly announced their relationship in which Citi will use Pismo's technology platform to help strengthen Citi's corporate demand deposit accounts (DDA), to clients worldwide. Citi TTS continues to migrate its solutions, services, and infrastructure to create "always on" capabilities aimed to improve the overall client experience and provide clients with the ability to operate DDA capabilities in real-time with 24x7 processing. Upgrading the current DDA infrastructure is a core element to the TTS technology revamp strategy, allowing for better scalability and increased processing volumes. Stephen Randall, Global Head of Liquidity Management Services, Citi Treasury and Trade Solutions, said, "Pismo was selected based on its core expertise and knowledge in cloud-based banking and payments capabilities. We look forward to working together and exploring different ways in which our relationship can drive Citi's work to help deliver clients' global ambitions." Ricardo Josua, Pismo CEO and co-founder, said, "We are deeply honoured to serve Citi as a key part of its journey. This relationship will help establish Pismo as one of the leading players in the cloud-native core banking space. Citi's selection of Pismo is a resounding endorsement of our decision to stay true to our cloud-native architectural roots and our decision to start expanding internationally in 2021." Citi's relationship with Pismo also creates value for Citi clients by helping to deliver: A nimble and scalable microservice-based ecosystem free of market-specific hardcoded applications, allowing for faster delivery of enhancements, easier integration across products and a globally consistent experience High volume 24x7 processing and real-time data availability, which will enable clients to make more efficient cash management decisions while taking advantage of Citi's global network Pismo's cloud-based core solutions are initially planned to be deployed by Citi in the U.S. market. Citi Treasury and Trade Solutions (TTS) helps enable our clients' success by providing an integrated suite of innovative and tailored cash management and trade finance services to multinational corporations, financial institutions, and public sector organizations across the globe. Based on the foundation of the industry's largest proprietary network with banking licenses in over 90 countries and globally integrated technology platforms, TTS continues to lead the way in offering a comprehensive range of digitally enabled treasury, trade, and liquidity management solutions. About Citi Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in nearly 160 countries and jurisdictions, providing corporations, governments, investors, institutions and individuals with a broad range of financial products and services. Additional information may be found at www.citigroup.com | Twitter: @Citi | LinkedIn: www.linkedin.com/company/citi | YouTube: www.youtube.com/citi | Facebook: www.facebook.com/citi About Pismo Pismo is a technology company providing an all-in-one processing platform for banking, payments, and financial markets infrastructure globally. Large banks, marketplaces, and fintech companies use our cloud-native microservices platform to launch next-generation solutions and move from legacy systems to the most advanced technology in the market. The Pismo cloud-based platform empowers firms to build and launch financial products rapidly, scaling as they grow to have a broader audience while keeping high security and availability standards. Additional information may be found at www.pismo.io Media Contacts: Nina Das Citi Institutional Clients Group+1 (212) 816-9267 Nina.Das@citi.com PismoPatricia Bartuira+1 (786) 270-6253marketing@pismo.io
Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaign Novavax shared data demonstrating that its XBB.1.5 COVID vaccine candidate induces functional immune responses to XBB subvariants including XBB.1.5, XBB.1.16 and XBB.2.3 If authorized, Novavax's protein-based vaccine candidate would be the only non-mRNA XBB.1.5 vaccine available in the U.S. Novavax intends to supply vaccine globally, consistent with FDA, WHO and EMA recommendations GAITHERSBURG, Md., June 16, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, participated in today's U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee's (VRBPAC) meeting, which resulted in a unanimous vote recommending updating the current COVID vaccine composition to a monovalent XBB-lineage. "Novavax expects to be ready for the commercial delivery of a protein-based monovalent XBB COVID vaccine this fall in line with today's VRBPAC recommendation," said John C. Jacobs, President and Chief Executive Officer, Novavax. "In partnership with regulators and public health authorities, Novavax has been developing and manufacturing this vaccine candidate, and now that we are nearing harmonization on guidance from the FDA, the World Health Organization and European Medicines Agency, we believe we are in a better position to offer an alternative vaccine choice for individuals worldwide." Novavax presented data at the VRBPAC meeting that supports the recommendation to vaccinate this fall with a monovalent XBB strain. Novavax data showed that its XBB.1.5 COVID vaccine candidate induced functional immune responses for XBB.1.5, XBB.1.16 and XBB.2.3 variants, indicating a broad response that could potentially be applicable for forward-drift variants. Novavax will seek updated FDA labeling for its XBB COVID vaccine candidate with the goal of it being available and accessible on par with other COVID vaccines. Authorized Use of the Novavax COVID-19 Vaccine, Adjuvanted in the U.S.The Novavax COVID-19 Vaccine, Adjuvanted vaccine has not been approved or licensed by the U.S. FDA, but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) as a primary series in individuals 12 years of age and older. The Novavax COVID-19 Vaccine, Adjuvanted vaccine is also authorized to provide a first booster dose at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. IMPORTANT SAFETY INFORMATIONContraindicationsDo not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted. Warnings and PrecautionsManagement of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Novavax COVID-19 Vaccine, Adjuvanted. Monitor the Novavax COVID-19 Vaccine, Adjuvanted recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control (CDC) and Prevention guidelines. Myocarditis and Pericarditis: Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of the Novavax COVID-19 Vaccine, Adjuvanted (see Full EUA Prescribing Information). The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#myocarditis-pericarditis). Syncope (fainting): May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting. Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Novavax COVID-19 Vaccine, Adjuvanted. Limitations of Vaccine Effectiveness: The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients. Adverse ReactionsAdverse reactions reported in clinical trials following administration of the Novavax COVID-19 Vaccine, Adjuvanted include injection site pain/tenderness, fatigue/malaise, muscle pain, headache, joint pain, nausea/vomiting, injection site redness, injection site swelling, fever, chills, injection site pruritus, hypersensitivity reactions, lymphadenopathy-related reactions, myocarditis, and pericarditis. Myocarditis, pericarditis, anaphylaxis, paresthesia, and hypoesthesia have been reported following administration of the Novavax COVID-19 Vaccine, Adjuvanted outside of clinical trials. Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Novavax COVID-19 Vaccine, Adjuvanted. Reporting Adverse Events and Vaccine Administration Errors The vaccination provider enrolled in the federal COVID-19 Vaccination Program is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS): vaccine administration errors whether or not associated with an adverse event, serious adverse events (irrespective of attribution to vaccination), cases of myocarditis, cases of pericarditis, cases of Multisystem Inflammatory Syndrome (MIS), in adults and children, and cases of COVID-19 that results in hospitalization or death. Complete and submit reports to VAERS online: For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words "Novavax COVID-19 Vaccine, Adjuvanted EUA" in the description section of the report. To the extent feasible, report adverse events to Novavax, Inc. using the following contact information or by providing a copy of the VAERS form to Novavax, Inc. Website: www.NovavaxMedInfo.com, Fax Number: 1-888-988-8809, Telephone Number: 1-844-NOVAVAX (1-844-668-2829). Please click to see the Novavax COVID-19 Vaccine, Adjuvanted Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and EUA Full Prescribing Information. Please click to see the Fact Sheet for Recipients and Caregivers. About NovavaxNovavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID, influenza, and COVID and influenza combined. Please visit novavax.com and LinkedIn for more information. Forward-Looking StatementsStatements herein relating to the future of Novavax, its operating plans and prospects, the ongoing development of NVX-CoV2373, XBB variant vaccines candidates, the scope, timing and outcome of future regulatory filings and actions, the potential impact and reach of Novavax and NVX-CoV2373 and its XBB variant candidates in addressing vaccine access, protecting populations, the efficacy, safety intended utilization, and the expected administration of NVX-CoV2373 and XBB vaccine candidates are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; unanticipated challenges or delays in conducting clinical trials; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts:InvestorsErika Schultz240-268-2022ir@novavax.com MediaAli Chartan240-720-7804media@novavax.com
這一健全的網絡安全課程即將會引入新的研究和證書 美國密歇根州伊普西蘭蒂2023年6月16日 /美通社/ -- GameAbove at Eastern Michigan University 是一個由校友領導的慈善組織，致力提升學術和運動項目，該組織宣布向大學的工程與科技學院 (GACET) 捐贈 160 萬美元。這項新的承諾將支持推出嵌入式系統的網絡安全倡議、提升網絡安全和物聯網方面的課程、引入汽車和流動設備服務的網絡安全之研究，以及建立可滿足學生和商業專業人士需求的專門網絡安全證書課程。 EMU GameAbove 工程與科技學院 GameAbove 主席 Keith J. Stone 表示：「我們的目標一直都是讓 GameAbove 工程與科技學院因全國最優秀的網絡安全課程而為人所知。我們不會偏離這個質量指標。GameAbove、Qatu 院長和東密歇根大學 (EMU) 的領導層目前採取的措施（包括這項捐款），證明了我們全團結一致，並全力提供適當資源，以確保該計劃持續成功。」 GACET 資訊安全與計算機應用學院的網絡安全課程是 EMU 其中一個發展最快的主修課程，亦是全美在提供防禦網絡攻擊和保護敏感個人資料的教育和培訓方面之領先者。它是美國其中一家最早提供網絡安全主修課程並獲得 ABET 認證和美國國家安全局 (NSA) 認證的學校。該課程提供學士學位和碩士學位，並提供線上和面授課程靈活組合，以滿足個人化教學和以職業為導向的學生和專業人士之需求。 從 2024 年開始，EMU 將提供以下網絡安全相關課程： 證書課程 全新網絡安全基礎 學士學位課程 資訊保密及網絡防禦 [學士學位] 資訊科技 [學士學位] 數碼鑑識和事故應變副修課程 資訊保障合規副修課程 碩士學位課程 網絡安全 [碩士學位] 可在線上學習 網絡安全 [碩士學位 + 學士學位] 今年，NSA 重新指定 EMU 的 GACET 為國家網絡防禦學術卓越中心 (National Center of Academic Excellence in Cyber Defense)，有效期至 2028 學年。在 2022 年，AcademicInfluence.com 評選最佳線上網絡安全學士學位課程 (Best Online Bachelor's in Cybersecurity)，其中 GACET 的資訊保密及網絡防禦學士學位課程排名全美第七，亦是密歇根州唯一打入前 10 名的大學。 憑藉接近 100% 的就業率，擁有網絡安全學位的 EMU 學生在 Google、Amazon、美國國土安全部和 NSA 等機構展開他們的職業生涯。找到與所學領域相關的就業機會是學生成功轉入職場最關鍵的一步。GameAbove 會透過將網絡安全學生與 GameAbove 的強大機構網絡連繫起來，與尋找全美頂尖網絡安全課程畢業生的業界領袖建立夥伴關係，在為學生提供就業機會方面繼續扮演關鍵角色。 EMU 校長 James Smith 表示：「我們十分感謝 GameAbove 校友組織的支持。成功校友的投入和奉獻，以及 GameAbove 對為東密歇根大學學生創造新機會的決心絕無僅有。GameAbove 會對我們為學生開發教育和職業機會的工作持續帶來直接影響，如果沒有 GameAbove，這些機會可能不會存在。」 GameAbove 工程與科技學院院長 Mohamad Qatu 表示：「網絡安全和其他相關領域（包括人工智能、物聯網和嵌入式系統），是個人以及公營和私營機構僱主最感興趣的發展領域之一。這些學習和研究領域在各方面影響著我們的生活。這些領域的就業增長在全美和全球都處於最高水平。」 Qatu 表示：「我們十分感謝 GameAbove 及其領導層的慷慨捐贈，以及出色的合作和支持。這種支持將幫助我們提供更多課程，透過供應強大的證書來提供更多進入該重要領域的途徑，並且提升我們的研究，以成為這個重要領域的全美領袖。」 GameAbove 已經向 EMU 捐贈超過 2,800 萬美元，支持或建立可激發創新和學術進步的項目。這些項目包括教職員提升培訓、為學生提供財政援助，以及改善 EMU 的設施以促進學生運動員的成就。 如需了解更多關於 GameAbove 工程與科技學院，以及資訊安全與計算機應用學院的資訊，請瀏覽此網站。 東密歇根大學簡介 東密歇根大學成立於 1849 年，是密歇根州第二古老的公立大學。目前學校為超過 14,000 名學生提供人文、科學和專業領域的學士、碩士、專家、博士和證書學位課程。透過學校的文理學院、商學院、教育學院、工程與科技學院、健康與人類服務學院，以及研究院，提供超過 300 個主修課程、副修課程和專業方向。國家出版物經常表揚 EMU 的卓越、多元化，以及對應用教育的投入。請瀏覽有關大學排名和引以為傲的地方之網站以了解更多資訊。如需了解更多關於東密歇根大學的資訊，請瀏覽大學網站。如要獲取大學的最新消息、活動和宣布，請瀏覽 EMU Today。 GameAbove 簡介 GameAbove at EMU 集中透過教育體驗的轉型和啟發，幫助塑造、啟發和支持現有和未來的東密歇根大學學生，並在學習上推向新的高度。GameAbove 立志透過探索和支持創新的財務模型來維持大學的可持續發展、改善校園環境、提高體育水平、推廣開創性的學術項目，以及在社區中進行創造性的捐贈，從而協助改進高等教育體驗。如需了解更多資訊，請瀏覽 www.gameabove.com。 GameAbove_Logo_1
16家沙特和國際公司參與拍賣，購買碳信用額度最多的公司為沙特阿美、沙特電力公司（SEC）和 ENOWA（NEOM的子公司） 此次拍賣提供了高質量、符合 CORSIA 標準並在 Verra 註冊的碳信用額度 今天的拍賣打破了 2022 年 10 月上一次自願碳信用額度拍賣所創下的紀錄，當時售出了 140 萬噸碳信用額度 沙特阿拉伯利雅得 2023年6月16日 /美通社/ -- Regional Voluntary Carbon Market Company (RVCMC) 今日宣布，其在有史以來規模最大的自願碳信用拍賣中成功拍賣了逾 220 萬噸碳信用。此次拍賣於 2023 年 年 6 月 14 日在肯尼亞內羅畢舉辦。 Delegates from Aramco, Saudi Electricity Company and ENOWA the three companies that purchased the most amount of credits at RVCMC’s carbon credit auction event –the largest of its kind 此次拍賣提供了高質量、符合 CORSIA 標準並在 Verra 註冊的碳信用額度，支持各行各業的買家在全球轉型中發揮自己的作用。RVCMC 致力於確保自願碳信用的購買超越價值鏈中有意義的減排。 16 家沙特地區和國際實體參與了此次拍賣，其中沙特阿美、沙特電力公司 (SEC) 和 ENOWA（NEOM 的子公司）購買了最多的碳信用額度。本次拍賣的其他中標人如下： Abdul Latif Jameel Fruiz Marine Corp (Costamare) GOLF SAUDI Gulf International Bank International Islamic Trade Finance Corporation Olayan Financing Company SAUDIA Saudi Arabian Mining Company (MA'ADEN) Saudi Aramco Base Oil Company (Luberef) Saudi Basic Industries Corporation (SABIC) Saudi National Bank Saudi Telecommunication Company (STC) Yanbu Cement Company 拍賣清算價格為每噸碳信用額度 23.50 沙特里亞爾。 一攬子信用包括 18 個項目，囊括了 CO2 避免和去除的組合，包括改進的清潔爐灶和可再生能源項目等項目。四分之三的碳信用額度來自中東、北非和撒哈拉以南非洲國家，包括肯尼亞、烏干達、布隆迪、盧旺達、摩洛哥、埃及和南非。 今日大獲成功的拍賣表明沙特阿拉伯致力於根據沙特綠色倡議和 2030 年願景應對氣候變化。 除了今天的拍賣活動外，RVCMC 還分別與 Eveready East Africa Plc 和 Carbon Vista Nigeria LP 簽署了諒解備忘錄，以便在肯尼亞、尼日利亞及其他地區開展高質量、有影響力的碳項目。這標誌著 RVCMC 與非洲主要機構之間的重要承諾。 RVCMC 行政總監 Riham ElGizy 表示：「我們需要使用所有可用工具來應對氣候變化已產生的破壞性影響。此次拍賣展示了自願碳市場在推動最需要資金的領域可以發揮的作用 ，在南方世傑開展氣候行動並改善生計。」 「今天，我們完成了有史以來規模最大的高質量自願碳信用額度拍賣，售出超過 220 萬噸。這是繼去年 10 月拍賣的 140 萬噸之後的又一次拍賣。 」 「我們的目標是到 2030 年成為全球最大的自願碳市場之一，每年補償數億噸碳排放，並為全球淨零目標做出貢獻。迄今為止，我們在短短的時期內所取得的成就表明了我們對長期成功的承諾，以及實現我們雄心壯志的能力。」 RVCMC 由 Public Investment Fund (PIF) 和 Saudi Tadawul Group 成立，旨在提供指導和資源，以支持中東和北非地區的企業和行業在全球淨零過渡中發揮作用。其使命是為中東和北非地區自願碳信用額度的產生和使用創造強大而成功的市場，並支持全球向低碳經濟轉型。 聯絡方式： 如需咨詢如何參與 RVCMC 自願碳市場，請聯絡：MVCM@pif.gov.sa 有關 RVCMC 的媒體查詢，請聯絡：RVCMC@teneo.com 編者按 關於 RVCMC RVCMC 於 2022 年 10 月由 Public Investment Fund (PIF) 和 Saudi Tadawul Group 成立。PIF 持有該公司 80% 的股份，Tadawul Group 持有 20% 的股份。RVCMC 正在快速創建具有全球影響力的大規模、可信自願碳市場。市場優先考慮高質量的碳信用和積極的氣候行動。該公司正在創建一個生態系統，涵蓋了用於氣候緩解項目的投資基金、碳信用交易所和幫助組織了解如何脫碳的諮詢服務。 在 Linkedin 上關注我們 https://www.linkedin.com/company/voluntarycarbonmarket/ 在 Twitter 上關注我們：https://twitter.com/vcm_ar https://twitter.com/vcm_en 瀏覽我們的網站：https://vcm.com.sa Hon. Moses Kuria, Cabinet Minister, Ministry of Investments, Trade & Industry, The Republic of Kenya, addresses delegates at RVCMC’s largest ever auction of voluntary carbon credits Riham ElGizy, CEO RVCMC addresses partners and buyers at world's largest carbon credit auction event in Nairobi, Kenya
~Operated by a Global Community Leaders based at "DG717" in San Francisco~ DG launches a STARTUP STUDIO "GenLab" for the next-generation entrepreneurs working with Generative AI at "DG717," DG's incubation center in San Francisco. Based on the "Global Incubation Stream" that DG has spent more than 20 years building, DG will gather entrepreneurs and engineers based in Silicon Valley and create a community that will attract entrepreneurs from all over the world. TOKYO, June 16, 2023 /PRNewswire/ -- Digital Garage, Inc. (TSE Prime section: 4819; HQ: Tokyo; Representative Director, President Executive Officer and Group CEO: Kaoru Hayashi; DG) opened its incubation center, "DG717," on Market Street in San Francisco in 2013. DG has a strong track record of supporting startups in various web3-related spaces, and the business community that DG has built over the past decade has become a landmark in San Francisco as a connecting hub for startups and investors. It has also functioned as a West Coast web3 community base camp for several years. DG has supported the global expansion of Japanese startups with its "Open Network Lab," a startup incubation program launched in 2010. DG has also implemented cutting-edge technologies globally, including supporting Twitter's entry into the Japanese market. San Francisco's business ecosystem experienced radical change due to the COVID pandemic. After several years of depopulation, the emergence of startups in the web3 and Generative AI spaces, such as OpenAI, is now transforming San Francisco into a new gateway city for the next-generation tech companies, including those in Silicon Valley. Amid this significant technological shift, DG launches "GenLab," a STARTUP STUDIO to support startups that create new value with generative AI and its related technologies, with "DG717" as the center of its activities. The startups in "GenLab" are primarily next-generation entrepreneurs, engineers, designers, and creators who can develop innovative concepts and services using generative AI. The most outstanding feature of "GenLab" is that its base of operations, "DG717," is in the center of San Francisco, a city full of people, information, and financial resources. In addition to Hayashi and Ito, co-founders of DG, who have been engaged in fostering various businesses as pioneers of the Internet business in Japan, DG has invited global IT leaders as advisors to support the startups. Greg Pass, former CTO of Twitter, Inc. (Twitter) and a key contributor to Cornell Tech, a tech campus on the U.S. East Coast, and Dr. Abdur Chowdhury, Chief Scientist at Twitter, as well as other pioneers in the U.S. tech community, will support startups as advisors. Also, Daniel Riedel, an entrepreneur and expert in the security space, will manage "GenLab" as Executive Director. Besides, businesses can grow globally through partnerships and fundraising utilizing DG's global networks and technical support from DG's research and development organizations, such as "DG Lab" and "DA Lab." After carefully selecting entrepreneurs for investment, "GenLab" will differentiate itself from others by establishing a unique "GenLab" method that provides financial support and helps them implement their services into society. Comment from Daniel Riedel, Executive Director of GenLab As AI technology evolves, it is essential that we foster sustainable and ethical development in the industry. Digital Garage's GenLab Venture Studio aims to create an environment where businesses and technologies prioritize the betterment of society and the environment, rather than solely focusing on profit. Comment from Kaoru Hayashi, Representative Director, President Executive Officer and Group CEO of Digital Garage, Inc. Since its establishment, DG has supported Japanese and international startups and built its startup network, "Global Incubation Stream." Global leaders such as Greg Pass, original member and former CTO of Twitter (now Professor of Practice, Cornell Tech), and Dr. Abdur Chowdhury, former Chief Scientist of Twitter (now CEO & Co-founder, Aura Frames), will also participate in "GenLab." Using a method that differentiates us from other investment funds, we will discover new talent to create the next Twitter and Google companies. Comment from Joichi Ito, Director, Senior Managing Executive Officer and Chief Architect of Digital Garage, Inc. Neural networks predict based on data patterns, but they do not understand the 'why.' However, we need to think beyond just Large Language Models (LLMs) and consider an AI that not only understands like humans but also amplifies intelligence and improves well-being. For instance, probabilistic computing allows us to encode and amplify the 'rules' that underpin human knowledge and reasoning. Through "DALab" that I lead, we plan to support initiatives and startups that are willing to be part of the journey with us. Startups interested in joining "GenLab" or interested in a partnership please contact us at genlab@garage.co.jp. If you have a question, don't hesitate to get in touch with us!Email: dg-cc@garage.co.jp
A12 藝術空間
Type-C
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
